Clinical Trial Detail

NCT ID NCT01811212
Title Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

thyroid gland cancer

Therapies

Cabozantinib

Age Groups: adult

No variant requirements are available.